Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

PETRI DISH PERSPECTIVES

PETRI DISH PERSPECTIVES artwork

Episode 71: Fate of Pharma M&A

Sep 3, 202622 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Send us Fan Mail In this episode of Petri Dish Perspectives, we take a step back from individual companies to examine one of the most powerful forces shaping the pharmaceutical industry: M&A, licensing, and the global competition for innovation. We explore how today's pharmaceutical giants were built through decades of consolidation, from Pfizer, GlaxoSmithKline, and Novartis to some of the industry's biggest modern transactions and why dealmaking has increasingly become essential for companies facing massive patent cliffs. But modern pharma is changing. Instead of relying solely on internal R&D or pursuing enormous megamergers, companies are increasingly acquiring targeted biotechs, licensing individual assets, and looking outside traditional innovation hubs for their next blockbuster. We'll also dive into one of the biggest shifts happening in biotech today: the rise of China and Asia as sources of innovative drug development. Western pharmaceutical companies are increasingly licensing molecules and technologies developed outside the U.S. and Europe, even as governments push for supply-chain independence and greater scrutiny of strategic relationships with China. What happens when the pharmaceutical industry is becoming more global while geopolitics is becoming less global? From the biggest deals in pharmaceutical history to the future of cross-border biotech partnerships, this episode asks a bigger question: Has Big Pharma become too dependent on buying innovation rather than building it? And if the best science can increasingly come from anywhere in the world, who will ultimately control the future of medicine? Because pharmaceutical M&A isn't just about buying companies. It's about deciding who gets to own the future of medicine. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #Pharma #Biotech #PharmaMA #BiotechMA #DrugDevelopment #BigPharma #PharmaceuticalIndustry #BiotechInnovation #Healthcare #LifeSciences #BusinessDevelopment #Licensing #PatentCliff #ChinaBiotech #GlobalHealth #Geopolitics #DrugDiscovery #Innovation #HealthcareInnovation Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Episode 82: Dr. Natalie Ma on Building Virtual Humans to Predict Drug Safety

    Nov 19, 202655 minAudio

    Send us Fan Mail After earning a PhD in molecular biology at Yale, Dr. Natalie Ma moved from the bench to the business side of science to tackle drug development’s biggest problem: roughly 90% of programs fail, often...

    Credit the people on this episode

  2. Episode 81: Mithril Medicine (Now Anthropic)

    Nov 12, 202626 minAudio

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Mithril Medicine, the one-person biotech that Anthropic just acquired and the story behind the man who built it. Cody Tranbarger spent six years...

    Credit the people on this episode

  3. Episode 80: Dr. Meesha Dogan on Using AI and Epigenetics to Detect Heart Disease Early

    Nov 5, 202647 minAudio

    Send us Fan Mail After a two-generation family history of heart disease, Dr. Meesha Dogan set out to change how the disease is detected. As founder and CEO of Cardio Diagnostics, she built and commercialized what the...

    Credit the people on this episode

  4. October 2026: Biotech & Pharma NEWS Roundup

    Nov 1, 20269 minAudio

    Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for October 2026! This month was defined by a wave of oncology approvals, a head-to-head data drop that reshuffled...

    Credit the people on this episode

  5. Episode 79: Endeavor Health

    Oct 29, 202617 minAudio

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Endeavor Health, the Chicago-area hospital system most Illinoisans have driven past but couldn’t name. Born from Evanston Hospital in 1891, grown...

    Credit the people on this episode